Latest News

On April 7, the Centers for Medicare and Medicaid Services (CMS) released a decision for Medicare coverage of Aduhelm (aducanumab).

CMS will cover Aduhelm under coverage with evidence development (CED). This means Aduhelm is covered for those who are participating in clinical trials.

The Penn Memory Center plans to be a testing site for ENVISION, the study to verify the clinical benefit of Aduhelm.

Penn Memory Center Co-Director Dr. Jason Karlawish said the CMS plan came from a position of “reasonableness and proportionality.” His complete reflection on the announcement can be found below.

Aduhelm was FDA-approved in June 2021 for the treatment of Alzheimer’s disease. You can read more about the history of Aduhelm and the science behind the drug on our Aduhelm question and answer page.

If you have questions about the CMS coverage decision, please send them to PennMemoryCenter@pennmedicine.upenn.edu. We will answer them as quickly as possible and post answers to our Aduhelm question and answer page.

After her husband developed Alzheimer’s disease dementia, Hilda Pridgeon turned to Medicare for help. When a pathway to resources wasn’t offered, she paved her own, fiercely advocating for better supports for patients, caregivers, and families. Hear about Hilda’s life and legacy from PMC Co-Director Jason Karlawish, MD.

You can also read about Hilda in ‘Part Two: The Birth of Alzheimer’s Disease’ of Dr. Karlawish’s book “The Problem of Alzheimer’s.” Learn more: https://www.jasonkarlawish.com/

By Cait Kearney

In 2013, Sarah was diagnosed with dementia caused by Alzheimer’s disease. In the years to follow, Sarah’s communication skills declined, and she stopped interacting with people. Occasionally, when looking at her image in the mirror, she would mumble a few incomprehensible sounds, but otherwise she didn’t speak.

Twice, Sarah did something that startled her family — she suddenly began saying words that were recognizable. She clearly said to her husband, on two occasions, “I’m scared. I want you to come with me.”

Shaken by the experience, he sought advice from Sarah’s physician.

These moments of sudden, clear communication in someone with progressive neurodegenerative disease, like those detailed by Sarah’s family, are episodes of what researchers call “paradoxical lucidity.”

“A person seems to be lost to their disease, but then there’s this unexpected and fleeting spark of clarity,” said Andrew Peterson, PhD, MA, a philosopher for the Penn Program on Precision Medicine for the Brain (P3MB) who studies paradoxical lucidity. “It could transform the way we think about dementia.”

By Alison Lynn, PMC associate director of social work

There was a time when it felt shameful to tell someone you go to therapy. Luckily, over the past few decades, it’s become increasingly normal to be open about ones need for professional support. Particularly post-pandemic, it is impossible to scroll through Instagram without seeing some kind of infographic or inspirational story related to mental health. But, despite this wealth of new information, many still don’t know what actually happens at therapy in enough detail to decide whether it might be helpful for them. What happens in the treatment room (or, on Zoom) can feel mysterious and intimidating.

In this two-part series, I’ll explain how to get started and what to expect from a first session, as well as how therapy can specifically help individuals with Alzheimer’s disease and their family caregivers.

On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials.

Penn Memory Center (PMC) Co-Director Jason Karlawish, MD, joined the Dementia Matters podcast to discuss the recent proposal, share his reaction to the decision, and tell you how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.

Discrimination, mistrust of medical professionals, and other barriers have caused Black and African Americans to be underrepresented among Alzheimer’s disease and related dementias (ADRD) researchers and research participants.

Increasing the representation of Black and African Americans in ADRD research is essential to developing treatments and providing quality care.

Learn more about three featured researchers at PMC who are breaking boundaries and working to advance equity in ADRD research.

Estevana Isaac

Estevana Isaac, MD
Role at PMC: Clinical fellow
Research interest: Disparities in health outcomes for patients with diverse cultural backgrounds

“As a clinical doctor, in addition to providing medical and social support to meet daily needs, I will continue to educate the public, patients, and caregivers to ensure safer environments. As a health services researcher, I intend to focus on solutions to better coordinate care and decrease costs for vulnerable patient populations as such. As a Black woman, I expect that my presence in these arenas continues to decrease biases and open more doors for diverse persons and perspectives, ultimately changing the face of healthcare.”